Sir, Management of childhood pemphigus vulgaris is difficult and warrants concerns for side effects of immunosuppressive therapy. As long-term use of potent corticosteroids can cause systemic side effects, choice of nonsteroidal immunosuppressive agent is very important to maintain long-term remission. We report a case of extensive childhood pemphigus vulgaris, who was successfully treated with long-term levamisole therapy along with low dose steroid and did not relapse.
Five months back, the patient developed itchy fluid filled lesions over scalp which progressed to involved his face, trunk, and extremities. He went to a government hospital, where he was diagnosed as a case of pemphigus vulgaris and treated with oral prednisolone and dapsone. He showed improvement after treatment for a month, but relapsed, 1 month before he presented to us.
At our hospital, he was treated with intravenous dexamethasone and antibiotics, to which he responded but relapsed after 1 month. He was then started on levamisole, in a dose of 1.5 mg/kg/day: 50 mg once daily, alongwith oral prednisolone 30 mg. The patient responded drastically and his lesions resolved within a month. Oral prednisolone was tapered gradually (by 5 mg every 15 days) to a maintenance dose of 5 mg, every alternate day within 3 months. He has maintained remission since then.
He continued his maintenance therapy of tab prednisolone 5 mg, alternate day and tablet levamisole 50 mg A/D for the next 18 months and then again tapered to oral prednisolone 5 mg, once a week and tab levamisole 50 mg A/D, which is being continued. No adverse effects were seen [ Figure 2 ].
Levamisole is an antihelminthic drug with immunomodulatory properties. It enhances innate immune responses and modulates cortisol levels during stress. [1] Further studies revealed that it stimulated T-helper 1 immunity by increasing serum levels of interferon-γ, interleukin (IL)-5 and tumor necrosis factor-α cytokines, IgG, IgM and total blood cell counts and upregulated the mRNA expression levels of IL-2, IL-4, and IL-5. At the cellular level, in the spleen, it increased immunoreactivity of CD4 and CD8. [2] However, the exact mechanism of action of levamizole in autoimmune inflammatory diseases remains unknown. In a study of patients with chronic oral ulcers, both levamisole 150 mg/day and prednisolone 15 mg/day for 3 consecutive days in a week was given. [3] The patients showed significant improvement; oral lesions resolving within 4-8 weeks and maintained remission. Oral ulcers due to lichen planus remained in remission for 6 months while remission lasted for 3 years in mucosal pemphigoid and pemphigus vulgaris. In combination with steroids, levamisole reduced the dose of steroids required for remission in patients of pemphigus vulgaris. [4] Levamisole has been used in pediatric population in steroid-dependent nephrotic syndrome which is an antibody-mediated autoimmune disease like pemphigus vulgaris, in a dose of 2.5 mg/kg (daily or alternate day) and it helped in reducing relapse, maintaining remission and lowering the dose of steroids; daily dosing being more effective than alternate day low dose prednisolone. [5, 6] No side effects associated with levamisole were reported in these patients. Levamisole is a relatively safer drug with minimal adverse effects. It includes rash, fever, nausea, abdominal cramps, taste alteration, alopecia, arthralgia, a flu-like syndrome and rarely, agranulocytosis, necrosis syndrome. [7] Based on proven safety of levamisole in children and its efficacy in antibody-mediated nephrotic syndrome in children, we decided to use levamizole in our patient.
Levamisole in Childhood Pemphigus Vulgaris
Thus, we report a successful use of levamizole in severe and recalcitrant pemphigus vulgaris in a child with no side effects. We suggest that it can be used as an excellent steroid sparing alternative, especially in children where there are concerns of side effects due to other immunosuppressive drugs.
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